- Gene Induced Immunotherapy
- Oncolytic Virotherapy
- Gene Transfer
Cancer gene therapy market size was valued at USD 629 million in the year 2021 and is anticipated to reach 3351.79 million at a CAGR of 27% by 2028 during the forecast period 2022-2028. Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells. In July 2017, Novartis received U.S. FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. In June 2013, BioSante Pharmaceuticals, Inc. completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company, ANI Pharmaceuticals, Inc.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, Lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.
Geographically, the cancer gene therapy is segmented into North America, Europe, Latin America, Asia- Pacific and the Middle East and Africa. North America leads the global cancer gene therapy market owing to the large pool of aging population and advancements in technology high investments in R & D activities along with the government support will boost industry demand. The U.K. market is anticipated to grow rapidly over the forecast period due to the rising occurrence of cancer along with the increase in acceptance of gene technology. Asia-Pacific is expected to witness high growth in cancer gene therapy market, due to increase in government initiatives, rising economy, and improvement in healthcare infrastructure in the region. Some of the key driving forces for cancer gene therapy market in emerging countries are increasing R&D investment, a large pool of patients and rising government funding.
Latin America
Europe
Asia Pacific
Middle East
North America
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1. Executive Summary |
| 2. Global Cancer Gene Therapy Market Introduction |
| 2.1. Global Cancer Gene Therapy Market – Taxonomy |
| 2.2. Global Cancer Gene Therapy Market –Definitions |
| 2.2.1. Therapy Type |
| 2.2.2. End User |
| 2.2.3. Region |
| 3. Global Cancer Gene Therapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Current Trends |
| 3.5. Global Cancer Gene Therapy Market Dynamic Factors - Impact Analysis |
| 3.6. Mergers, Acquisitions, and Collaborations |
| 4. Global Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 |
| 4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Cancer Gene Therapy Market, By Therapy Type, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.1. Gene Induced Immunotherapy |
| 5.1.1. Delivery of Cytokines Gene |
| 5.1.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Delivery of Tumor Antigen Gene |
| 5.1.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3. Market Opportunity Analysis |
| 5.2. Oncolytic Virotherapy |
| 5.2.1. Adenovirus |
| 5.2.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. Lentivirus |
| 5.2.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Retro virus |
| 5.2.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.2.4. Adeno Associated Virus |
| 5.2.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.4.3. Market Opportunity Analysis |
| 5.2.5. Herpes Simplex Virus |
| 5.2.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.5.3. Market Opportunity Analysis |
| 5.2.6. Alpha Virus |
| 5.2.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.6.3. Market Opportunity Analysis |
| 5.2.7. Vaccinia Virus |
| 5.2.7.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.7.3. Market Opportunity Analysis |
| 5.2.8. Simian Virus |
| 5.2.8.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.8.3. Market Opportunity Analysis |
| 5.2.9. Others |
| 5.2.9.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.2.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.9.3. Market Opportunity Analysis |
| 5.3. Gene Transfer |
| 5.3.1. Naked/Plasmid Vectors |
| 5.3.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.1.3. Market Opportunity Analysis |
| 5.3.2. Electroporation |
| 5.3.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.2.3. Market Opportunity Analysis |
| 5.3.3. Sonoporation |
| 5.3.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3.3. Market Opportunity Analysis |
| 5.3.4. Magnetofection |
| 5.3.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.4.3. Market Opportunity Analysis |
| 5.3.5. Gene gun |
| 5.3.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.5.3. Market Opportunity Analysis |
| 6. Global Cancer Gene Therapy Market, By End User, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 6.1. Hospitals and Clinics |
| 6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Biopharma and Biotechnology Companies |
| 6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Academic and Research Institutes |
| 6.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Global Cancer Gene Therapy Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific |
| 7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. MEA |
| 7.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Region, 2022 - 2028 |
| 8. North America Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 8.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Gene Induced Immunotherapy |
| 8.1.1.1. Delivery of Cytokines Gene |
| 8.1.1.2. Delivery of Tumor Antigen Gene |
| 8.1.2. Oncolytic Virotherapy |
| 8.1.2.1. Adenovirus |
| 8.1.2.2. Lentivirus |
| 8.1.2.3. Retro virus |
| 8.1.2.4. Adeno Associated Virus |
| 8.1.2.5. Herpes Simplex Virus |
| 8.1.2.6. Alpha Virus |
| 8.1.2.7. Vaccinia Virus |
| 8.1.2.8. Simian Virus |
| 8.1.2.9. Others |
| 8.1.3. Gene Transfer |
| 8.1.3.1. Naked/Plasmid Vectors |
| 8.1.3.2. Electroporation |
| 8.1.3.3. Sonoporation |
| 8.1.3.4. Magnetofection |
| 8.1.3.5. Gene gun |
| 8.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Hospitals and Clinics |
| 8.2.2. Biopharma and Biotechnology Companies |
| 8.2.3. Academic and Research Institutes |
| 8.2.4. Others |
| 8.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1. United States |
| 8.3.2. Canada |
| 8.4. North America Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
| 8.5. North America Cancer Gene Therapy Market Dynamics – Trends |
| 9. Europe Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 9.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Gene Induced Immunotherapy |
| 9.1.1.1. Delivery of Cytokines Gene |
| 9.1.1.2. Delivery of Tumor Antigen Gene |
| 9.1.2. Oncolytic Virotherapy |
| 9.1.2.1. Adenovirus |
| 9.1.2.2. Lentivirus |
| 9.1.2.3. Retro virus |
| 9.1.2.4. Adeno Associated Virus |
| 9.1.2.5. Herpes Simplex Virus |
| 9.1.2.6. Alpha Virus |
| 9.1.2.7. Vaccinia Virus |
| 9.1.2.8. Simian Virus |
| 9.1.2.9. Others |
| 9.1.3. Gene Transfer |
| 9.1.3.1. Naked/Plasmid Vectors |
| 9.1.3.2. Electroporation |
| 9.1.3.3. Sonoporation |
| 9.1.3.4. Magnetofection |
| 9.1.3.5. Gene gun |
| 9.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Hospitals and Clinics |
| 9.2.2. Biopharma and Biotechnology Companies |
| 9.2.3. Academic and Research Institutes |
| 9.2.4. Others |
| 9.3. Country Level Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. UK |
| 9.3.2. Germany |
| 9.3.3. France |
| 9.3.4. Italy |
| 9.3.5. Spain |
| 9.3.6. Rest of Europe |
| 9.4. Europe Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
| 9.5. Europe Cancer Gene Therapy Market Dynamics – Trends |
| 10. Asia Pacific Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 10.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Gene Induced Immunotherapy |
| 10.1.1.1. Delivery of Cytokines Gene |
| 10.1.1.2. Delivery of Tumor Antigen Gene |
| 10.1.2. Oncolytic Virotherapy |
| 10.1.2.1. Adenovirus |
| 10.1.2.2. Lentivirus |
| 10.1.2.3. Retro virus |
| 10.1.2.4. Adeno Associated Virus |
| 10.1.2.5. Herpes Simplex Virus |
| 10.1.2.6. Alpha Virus |
| 10.1.2.7. Vaccinia Virus |
| 10.1.2.8. Simian Virus |
| 10.1.2.9. Others |
| 10.1.3. Gene Transfer |
| 10.1.3.1. Naked/Plasmid Vectors |
| 10.1.3.2. Electroporation |
| 10.1.3.3. Sonoporation |
| 10.1.3.4. Magnetofection |
| 10.1.3.5. Gene gun |
| 10.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Hospitals and Clinics |
| 10.2.2. Biopharma and Biotechnology Companies |
| 10.2.3. Academic and Research Institutes |
| 10.2.4. Others |
| 10.3. Country Level Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. China |
| 10.3.2. India |
| 10.3.3. ANZ |
| 10.3.4. Japan |
| 10.3.5. Rest of APAC |
| 10.4. Asia Pacific Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
| 10.5. Asia Pacific Cancer Gene Therapy Market Dynamics – Trends |
| 11. Latin America Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 11.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Gene Induced Immunotherapy |
| 11.1.1.1. Delivery of Cytokines Gene |
| 11.1.1.2. Delivery of Tumor Antigen Gene |
| 11.1.2. Oncolytic Virotherapy |
| 11.1.2.1. Adenovirus |
| 11.1.2.2. Lentivirus |
| 11.1.2.3. Retro virus |
| 11.1.2.4. Adeno Associated Virus |
| 11.1.2.5. Herpes Simplex Virus |
| 11.1.2.6. Alpha Virus |
| 11.1.2.7. Vaccinia Virus |
| 11.1.2.8. Simian Virus |
| 11.1.2.9. Others |
| 11.1.3. Gene Transfer |
| 11.1.3.1. Naked/Plasmid Vectors |
| 11.1.3.2. Electroporation |
| 11.1.3.3. Sonoporation |
| 11.1.3.4. Magnetofection |
| 11.1.3.5. Gene gun |
| 11.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Hospitals and Clinics |
| 11.2.2. Biopharma and Biotechnology Companies |
| 11.2.3. Academic and Research Institutes |
| 11.2.4. Others |
| 11.3. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Rest of LA |
| 11.4. Latin America Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
| 11.5. Latin America Cancer Gene Therapy Market Dynamics – Trends |
| 12. MEA Cancer Gene Therapy Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
| 12.1. Therapy Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Gene Induced Immunotherapy |
| 12.1.1.1. Delivery of Cytokines Gene |
| 12.1.1.2. Delivery of Tumor Antigen Gene |
| 12.1.2. Oncolytic Virotherapy |
| 12.1.2.1. Adenovirus |
| 12.1.2.2. Lentivirus |
| 12.1.2.3. Retro virus |
| 12.1.2.4. Adeno Associated Virus |
| 12.1.2.5. Herpes Simplex Virus |
| 12.1.2.6. Alpha Virus |
| 12.1.2.7. Vaccinia Virus |
| 12.1.2.8. Simian Virus |
| 12.1.2.9. Others |
| 12.1.3. Gene Transfer |
| 12.1.3.1. Naked/Plasmid Vectors |
| 12.1.3.2. Electroporation |
| 12.1.3.3. Sonoporation |
| 12.1.3.4. Magnetofection |
| 12.1.3.5. Gene gun |
| 12.2. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Hospitals and Clinics |
| 12.2.2. Biopharma and Biotechnology Companies |
| 12.2.3. Academic and Research Institutes |
| 12.2.4. Others |
| 12.3. Country Level Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. GCC Countries |
| 12.3.2. South Africa |
| 12.3.3. Rest of MEA |
| 12.4. MEA Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
| 12.5. MEA Cancer Gene Therapy Market Dynamics – Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Urigen Pharmaceuticals Inc. |
| 13.2.2. GenVec.Inc |
| 13.2.3. Oxford BioMedica |
| 13.2.4. Vical |
| 13.2.5. ANI Pharmaceuticals, Inc. |
| 13.2.6. Genzyme Corporation |
| 13.2.7. Novartis AG |
| 13.2.8. Cell Medica |
| 13.2.9. Cell Genesys Inc. |
| 13.2.10. Adaptimmune Therapeutics plc |
| 13.2.11. Genelux Corporation |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |